Acquisitions roundup: BAE throws down $86 million for Fairchild Imaging

Here’s a roundup of companies announcing mergers and acquisitions:

• BAE throws down $86 million for Fairchild Imaging
  BAE Systems plc (OTC:BAESY) entered into a definitive agreement to acquire Fairchild Imaging Inc., a privately held company specializing in solid-state electronic imaging components, cameras, and systems for aerospace, industrial, medical, and scientific imaging applications. BAE Systems currently owns 8.7 percent of the equity of Fairchild Imaging and, upon completion of the acquisition for a cash consideration of approximately $86 million, will have acquired all of the remaining outstanding equity. The proposed acquisition of Fairchild Imaging reflects BAE Systems’ strategy to grow its electronic systems business and will complement existing electro-imaging capabilities, technologies and product offerings, according to the company.
  Read more
• IDEX buys out Advanced Thin Films
  IDEX Corp. (NYSE:IEX) entered into a definitive agreement to purchase Advanced Thin Films LLC. ATFilms, with approximately $9 million in revenue, specializes in optical components and coatings for applications in the fields of scientific research, defense, aerospace, telecommunications and electronics manufacturing. ATFilms’ core competence is in the design and manufacture of filters, splitters, reflectors and mirrors with the precise physical properties required to support their customers’ most challenging and cutting-edge optical applications. The Boulder, Col.-based copmany will operate within IDEX’s Health and Science Technologies segment as a part of the IDEX optical products platform. AT Films will be acquired for cash consideration of $32 million and is expected, inclusive of all potential earn-out, to be accretive to earnings in 2011. The acquisition is expected to close by the end of the month pending the discharge of indebtedness of the company.
  Read more
• inVentiv Health to acquire clinical development outsourcing businesses from Ingenix
  inVentiv Health, a provider of outsourced clinical development, launch and commercial services to the global health care industry, signed a definitive agreement to purchase the i3 clinical development businesses from Ingenix. The proposed transaction, covering businesses that generate approximately $400 million in annual gross revenue, is expected to close in the first half of this year. Upon close of the proposed transaction, inVentiv will acquire the following businesses from Ingenix: i3 Research, i3 Statprobe and i3 Pharma Resourcing. These businesses will retain the i3 brand name and will be aligned with inVentiv’s other clinical development offerings, advancing i3’s position as a global CRO serving pharmaceutical, biotech and medical device companies. Ingenix will align all of its commercialization, safety, regulatory and late phase service offerings under its newly-launched Ingenix Life Sciences division, according to the company.
  Read more
• NeoStem and Progenitor Cell Therapy close merger deal
  NeoStem Inc. (NYSE:NBS) and Progenitor Cell Therapy LLC closed of their previously announced merger transaction. NeoStem is an international biopharmaceutical company with a 51 percent ownership interest in a Chinese generic pharmaceutical manufacturing company and has stem cell operations in the U.S. and China, while Progenitor Cell Therapy is a privately held cell therapy company with operations on the east and west coast of the U.S. serving the cell therapy community with cGMP state-of-the art cell therapy manufacturing facilities, and processing and storage facilities for stem cells collected from the umbilical cord at birth.
  Read more
• Mould Technologies Group acquires Magor Mold
  Mould Technologies Group, which incorporates Diessenhofen, Switzerland-based Schöttli AG, has acquired all shares in San Dimas, Calif.-based Magor Mold Inc. MTG also owns s-mouldtech in Suzhou, China. The three mould engineering specialists have joined forces to provide customers, many of whom are medical device OEMs, with an enhanced portfolio of moulds from a single supplier, according to medtechinsider.
  Read more
• Report: Healthcare M&A activity for 2010 remained strong
  During 2010 and based on preliminary results, a total of 913 mergers and acquisitions were announced in 13 sectors of the health care industry, a 3 percent decrease from the 945 transactions announced in 2009, according to a report from Irving Levin Associates Inc. Based on prices revealed to date, a total of $206.5 billion was committed to finance the year’s 913 deals. This represents an 11 percent decrease from the $232.2 billion in 2009. In terms of dollars committed to merger and acquisition deals, 2010 is the fifth-largest year of the past 10 years.
  Read more

Table compiled by Irving Levin Associates.